Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Cureus|February 22, 2018
Survival and Failure Outcomes Predicted by Brain Metastasis Volumetric Kinetics in Melanoma Patients Following Upfront Treatment with Stereotactic Radiosurgery AloneMichael C LeCompte, Emory McTyre, Adrianna Henson, et al.
Neurosurgery Practice|February 17, 2025
Patterns of Failure Outcomes for Combination of Stereotactic Radiosurgery and Immunotherapy for Melanoma Brain MetastasesMohammed Abdulhaleem, Hannah Johnston, Ralph D'Agostino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 24, 2009
A phase I study of sunitinib plus bevacizumab in advanced solid tumorsBrian I Rini, Jorge A Garcia, Matthew M Cooney, et al.
Biorxiv : the Preprint Server for Biology|February 27, 2026
Enhancing Patient Lymphocyte Response to Peritoneal Malignancies Using a Personalized Immunocompetent Microfluidic Co-Culture PlatformCecilia R Schaaf, Damian C Hutchins, Tiefu Liu, et al.
Scientific Reports|October 9, 2019
CD138 plasma cells may predict brain metastasis recurrence following resection and stereotactic radiosurgeryMichael H Soike, Jennifer Logue, Shadi Qasem, et al.
Neuro-Oncology Practice|September 27, 2019
Immunotherapy is associated with improved survival and decreased neurologic death after SRS for brain metastases from lung and melanoma primariesClaire M Lanier, Ryan Hughes, Tamjeed Ahmed, et al.
Therapeutic Advances in Medical Oncology|January 22, 2024
Study protocol: phase II study to evaluate the effect of cetuximab monotherapy after immunotherapy with PD-1 inhibitors in patients with head and neck squamous cell cancerKimberly M Burcher, Chance H Bloomer, Elena Gavrila, et al.
International Journal of Radiation Oncology, Biology, Physics|July 3, 2020
Predictors of Adverse Radiation Effect in Brain Metastasis Patients Treated With Stereotactic Radiosurgery and Immune Checkpoint Inhibitor TherapyCorbin A Helis, Ryan T Hughes, Chase W Glenn, et al.
Oncoimmunology|November 3, 2018
Tumor mutational burden is a determinant of immune-mediated survival in breast cancerAlexandra Thomas, Eric D Routh, Ashok Pullikuth, et al.
Pageof 3